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Respiratory symptom perception research has focused mainly on respiratory sensations.
Because dyspnea is multidimensional, affective aspects should be investigated. Patients
with asthma (N ¼ 25) underwent a histamine provocation until a 20% fall in forced
expiratory volume in 1 s (FEV1). After each dose level, 6 symptoms of dyspnea intensity and
6 symptoms of dyspnea affectivity were rated. Individual perceptual sensitivity was
determined by calculating the linear slope between the fall in FEV1 and the increase in the
total symptom score, and for affective and sensory symptoms separately [Bijl-Hofland,
Folgering, van den Hoogen, et al. Perception of bronchoconstriction in asthma patients
measured during histamine challenge test. Eur Respir J 1999;14:1049–54]. Trait anxiety,
baseline state anxiety, daily asthma symptoms and catastrophizing during an asthma
exacerbation were also assessed. Sensitivity was unrelated to physiological indices of
disease severity (i.e., baseline FEV1 and histamine dose level at 20% fall in FEV1), whereas
it was positively related to trait anxiety, state anxiety, daily asthma symptoms and
catastrophic thinking during an asthma exacerbation in daily life. These relationships were
overall much stronger for affective than for sensory symptom slopes. In stepwise multiple
regressions, state anxiety was the best predictor of the affective symptom slopes, whereas
catastrophic thinking during an asthma exacerbation was the best predictor for the sensoryElsevier Ltd. All rights reserved.
ariance; ASC, asthma symptom checklist; CAS, catastrophizing about asthma scale; FEV1, forced
d corticosteroids; NA, negative affectivity; PANAS, positive and negative affect schedule; PC20,
e causing a 20% fall in FEV1; PS20, symptom scores corresponding to a 20% fall in FEV1; SD, standard
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S. De Peuter et al.926symptom slopes. The differentiation between sensory and affective components of
dyspnea adds to the understanding of respiratory symptom perception in asthma.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Poor symptom perception puts patients with asthma at
increased risk of severe attacks, because medication may be
delayed or omitted.1,2 Poor symptom perception may cause
mild asthma to deteriorate as inflammation stays unde-
tected.3 Because bronchial provocation tests provide in-
formation on the relatively rapid development of
bronchoconstriction, simultaneous symptom reports can
provide information about patients’ perceptual sensitivity.
It is important to identify determinants of poor percep-
tion, such as age, gender, severity of bronchial responsive-
ness3,4 and temporal adaptation. Few studies, however,
have investigated psychological variables. Spinhoven and
colleagues5 reported that anxiety associated with increasing
breathlessness led to more complaints at a reduction in lung
function of 20%. In addition, anxious perceivers had a higher
sensitivity for bronchoconstriction, despite similar airway
responsiveness compared to low anxious patients.
We wanted to investigate how psychological variables
influence breathlessness perception.
First, trait anxiety has been shown to be similar to
negative affectivity (NA; the tendency to experience a
broad range of negative emotions6,7). Research both in
patients with asthma and healthy participants consistently
found that persons with a high level of NA report more
symptoms than persons with a low level of NA, without
corresponding physiological differences.8–13 Also, high-NA
persons are less accurate in perceiving respiratory symptoms
than low-NA persons, especially in distressing situations.14,15
Because trait anxiety is used to describe a variety of
negative emotional states, more specific components may
distinctively influence symptom reporting and illness beha-
vior in asthma. In pain research, patients with catastrophic
thoughts about their pain report more pain, more intense
pain, more disability from their pain, and more interference
with their daily activities and other life domains.16,17
Recently, similarities between pain and dyspnea have been
described18,19 and first findings about the effect of cata-
strophic thinking in asthma have been reported.20 There-
fore, we included measures of trait and state anxiety, and of
catastrophic thinking about asthma.
Second, the perception of bronchoconstriction is gener-
ally measured in general terms of ‘dyspnea’ or ‘breath-
lessness’. However, dyspnea is not one-dimensional: clinical,
experimental, and neuroimaging data suggest that a
distinction between physical sensations and emotional
reactions to dyspnea is clinically useful.5,18,19,21–24 By
keeping symptom reports limited to physical sensations,
important aspects of the subjective experience of
bronchoconstriction/dyspnea may be overlooked.
In short, the aims of this study were (1) to investigate
individual differences in patients with asthma’s perception
of dyspnea induced by a standardized histamine provoca-
tion; (2) to test different aspects of dyspnea; and (3)evaluate the effect of anxiety and catastrophic thinking
about asthma on dyspnea.
Methods
Participants
We invited patients with asthma who had been referred to
the university hospital for a histamine provocation. Reasons
for referral were: regular control measurements of airway
reactivity—to assess the long-term development of the
disease, or diagnostic purposes. Inclusion criteria were: a
confirmed diagnosis of asthma (based on symptom reports,
lung function data, a positive reaction to asthma medica-
tion, and a positive response to the bronchial provocation),
age between 18 and 65, Dutch-speaking, baseline FEV1450%
of the predicted value, a provocative concentration of
histamine causing a 20% fall in FEV1 (PC20)p8mg/ml, and at
least two doubling doses of histamine (to be able to
determine the patients’ sensitivity during the test; see
further). Twenty-nine patients were invited to participate,
two were excluded because they did not understand Dutch,
one patient declined participation because of lack of time;
another patient said she was too anxious and preferred not
to answer any more questions. The final study sample
consisted of 25 patients with asthma (13 male, 12 female;
mean age ¼ 38.5; SD ¼ 13.6). According to GINA guidelines,25
18 patients had mild persistent asthma, 5 had moderate
persistent asthma. For two more patients, we had insuffi-
cient data to determine asthma severity. Seven patients
used inhaled corticosteroids (ICS) to control their disease.
The Medical Ethical Board of the hospital approved of the
study and all patients provided informed consent.
Subjective measures
We used the NA scale of the Positive and Negative
Affectivity Schedule (PANAS26) to measure trait anxiety:
Participants rated the degree to which 10 negative
adjectives are applicable to themselves. End points are
very little or not at all (scored 1) and very much (scored 5),
resulting in a total score between 10 and 50.
We used the validated Dutch translation of the Asthma
Symptom Checklist (ASC) to assess subjective asthma
symptoms.27,28 The ASC is a 36 item-checklist, consisting
of 6 subscales: symptoms of airway obstruction, dyspnea,
symptoms of hyperventilation, fatigue, anxiety, and irrit-
ability. The first three subscales measure the sensory aspect
of dyspnea, the latter three the affective aspect. Internal
consistency for five of the six subscales is high (Cronbach’s a:
ranging from 0.86 to 0.93) and acceptable for hyperventila-
tion complaints (Cronbach’s a: 0.7628). At baseline
(see Procedure section), patients rated how frequently
they experience each symptom during a typical asthma
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(scored 5; ‘‘ASC-Exacerbation’’). A second version of the
ASC measured symptom intensity at baseline on an 11-point
scale ranging from not at all (scored 0) to symptoms as bad
as possible (scored 10; ‘‘ASC-Now’’). To restrict completion
time and not to interfere with the standardized histamine
protocol, we constructed a third version, consisting of two
items per subscale (‘‘ASC-Short’’a). The ASC-Short was used
during the histamine provocation to measure symptom
intensity on an 11-point scale ranging from not at all
(scored 0) to symptoms as bad as possible (scored 10).
The Catastrophizing about Asthma Scale (CAS29) was used
to measure catastrophic cognitions about asthma. Patients
rated the extent to which 24 items expressing catastrophic
thoughts and feelings about asthma are applicable to
themselves. The scale has two subscales, one referring to
the situation of an asthma exacerbation (the ‘exacerbation’
scale), one referring to the situation in general, whenever
no exacerbation is present (‘general’ scale). The CAS has
high internal consistency (Cronbach’s a ¼ 0.93), excellent
test–retest reliability (r ¼ 0.94), and good construct
validity.29Histamine provocation
All patients underwent spirometry according to ERS guide-
lines30 on a Mass-flow Sensor (Sensormedics, Vmax 20C,
2000). Non-specific airway responsiveness to histamine was
measured according to the method described by Cockcroft
and colleagues.31 After determination of baseline FEV1
(expressed as the percentage of the predicted value) the
patient inhaled saline (NaCl; 0.9%) followed by progressive
doubling concentrations of histamine (0.25–8mg/ml; pre-
pared by the hospital pharmacy and stored at 4 1C) until the
FEV1 had fallen at least 20% below participants’ baseline
value or until the maximum concentration of 8mg/ml was
reached. Aerosols were generated by pressed air with a flow
of 6 l/min via a System 22 Disposable Sidestream Nebulizer
(Medic-Aid, Pagham, UK; mass median diameter 3mm,
respirable output 80%). Every aerosol pot contained 3ml of
test liquid (saline or histamine). Participants wore a nose
clip and inhaled the aerosols quietly at tidal volume through
a mouthpiece for 2min at 5min intervals. All substances
were inhaled at room temperature. FEV1 was measured 60
and 180 s after each inhalation, the lower value of both
measurements was used for analyses.
On the day of the study, patients had not taken any short-
acting b2-agonists and anticholinergics for 8 h, long-acting
b2-agonists and theophyllines for 24 h and antihistaminics
and long-acting anticholinergics for 48 h. Inhaled corticos-
teroids were allowed.aThe two items per subscale were selected on face validity. Items
were: ‘uncomfortable feeling in the chest’ and ‘chest filling up’ for
the obstruction subscale; ‘short of breath’ and ‘hard to breathe’ for
the dyspnea subscale; ‘fatigued’ and ‘no energy’ for the fatigue
subscale; ‘dizzy’ and ‘headache’ for the hyperventilation subscale;
‘scared’ and ‘worried’ for the anxiety subscale; and ‘cranky’ and
‘irritable’ for the irritability subscale.Procedure
When patients registered at the nurse’s desk on the day and
time of their scheduled appointment, they were invited to
participate in the study. The purpose of the study was
explained, patients who were willing to participate signed
the informed consent form and completed the question-
naires in the waiting room (Baseline measures: PANAS,
ASC-Exacerbation, CAS, ASC-Now). Next, they performed
baseline spirometry and patients with an FEV1450% of
predicted values continued with the histamine provocation.
After each inhalation (starting with NaCl) and before the
first FEV1 measurement, symptoms were assessed with the
ASC-Short. When participants’ FEV1 had fallen at least 20%
below baseline measures, participants received salbutamol
(Ventolins400 mg, GlaxoSmithKline) to guarantee maximal
reversion of the bronchoconstriction. Thereafter, they were
debriefed.Data reduction and analysisWe calculated Pearson’s product–moment correlations be-
tween symptom scores and lung function data both at
baseline and at the maximal fall in FEV1. We also correlated
symptom scores with the subjective measures.
The provocative concentration of histamine causing a 20%
fall in FEV1 (PC20) and the symptom scores corresponding to
a 20% fall in lung function (PS20) were determined by linear
interpolation from the last two points on the log dose–
response curve. We transformed all symptom scores to a
scale ranging from 0 to 50 so that the range of symptom
scores and the range of FEV1 were similar. Next, the
sensitivity of the perception of bronchoconstriction during
the histamine challenge was calculated by regressing the
changes in symptoms compared to the post-saline ratings on
the reduction in FEV1 as percentage of the post-saline value.
The change in FEV1 was placed on the x-axis as the
independent variable and the linear regression coefficient
(B) for symptoms was calculated. This slope is an index of
the perceptual sensitivity of an individual; the steeper the
slope, the more sensitive a person is. We performed this
analysis first for the ASC-Short total scores, and subse-
quently for the affective (subscales anxiety, irritability, and
fatigue) and sensory (subscales obstruction and dyspnea)
groups of symptoms separately [exploratory factor analysis
on data from a previous study (De Peuter et al., unpublished
data) suggested a three-factor solution with an affective
and a sensory factor as the first two factors; a third factor
grouped the ‘hyperventilation’ complaints. Because the
hyperventilation items had low factor loadings on this factor
we decided not to use the ‘hyperventilation’ scale in the
current analyses]. Slopes based on these different (sub)-
scores are given a subscript in the text referring to the
(sub)score they are based on, e.g. slopeTotal.
Next, we compared the different slopes using t-tests and
calculated Pearson’s product–moment correlations between
the slopes and other patient characteristics. Partial correla-
tions were used to control for differences in baseline FEV1
and highest histamine dose where appropriate.
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Table 1 Means (and standard deviations) from the
questionnaires completed before the histamine provoca-
tion.
Questionnaire data
ASC-Exacerbation total 2.5 (0.6)
Obstruction 2.7 (1.1)
Dyspnea 3.6 (1.1)
Anxiety 2.1 (0.9)
Irritability 2.4 (0.7)
Fatigue 2.9 (1.1)
Hyperventilation 1.8 (0.7)
ASC-Now total 1.5 (1.6)
Obstruction 1.7 (2.5)
Dyspnea 2.4 (2.8)
Anxiety 1.1 (1.4)
Irritability 1.6 (2.0)
Fatigue 1.9 (2.6)
Hyperventilation 0.5 (0.8)
PANAS—Trait anxiety 23.5 (6.4)
CAS—Catastrophic thinking
‘Exacerbation’ scale 17.9 (10.4)
‘General’ scale 11.9 (11.7)
Note: ASC-Exacerbation: frequency of symptoms during an
exacerbation on a scale from 1 (‘never’) to 5 (‘always’); ASC-
Now: intensity of symptoms before the histamine challenge
on a scale from 0 to 10. The range of the triat anxiety scale
was 10–50; Ranges for CAS scores are: CAS ‘exacerbation’:
0–52; CAS ‘general’: 0–44.
S. De Peuter et al.928We used forward stepwise multiple regression analysis to
assess the relative influence of the psychological variables
on participants’ sensitivity.
Finally, because 10 patients had a flat slopeAffective and
this constitutes 40% of our sample, we used 2-way ANOVA’s
to compare the group with a flat slope with the group with a
slope 40.
All analyses were performed with STATISTICA 7.1 (Stat-
Soft, Inc., Tulsa, USA).
Results
Baseline data
Means and standard deviations of the questionnaire data are
presented in Table 1. At baseline, symptom scores were low
(ASC-Now), although the value for dyspnea was well above 0.
Clinical characteristics are presented in Table 2. Baseline
FEV1 ranged from 69% to 127% of predicted values. In most
patients, FEV1 increased slightly after NaCl-inhalation
(maximum increase ¼ +7%; maximum fall ¼ 4%). Accord-
ingly, ASC-Short scores decreased from 1.6 (SD ¼ 1.7) at
baseline to 0.7 (SD ¼ 1.0) after NaCl-inhalation.
The correlations between baseline FEV1 values (before
NaCl inhalation) and baseline symptom reports (ASC-Now)
were of minor magnitude and not significant, with only the
correlations for the anxiety and irritability scale exceeding
|0.10| (r ¼ 0.16, P ¼ 0.47 and 0.13, P ¼ 0.55, respec-
tively).
Symptom perception
Absolute perceptual magnitude
The mean maximal reduction in FEV1 was 26.8% (SD ¼ 5.5;
range 20–44%). The mean symptom score associated with
this reduction in FEV1 was 2.3 (SD ¼ 2.0; range 0.2–8.5). The
partial correlation controlling for histamine dose between
these two variables was 0.40, P ¼ 0.054. The mean symptom
score at a reduction of 20% in FEV1 (PS20) was 1.9 (SD ¼ 1.7;
range 0.1–8.3).
Sensitivity
Two examples of individual slopes, one for a patient with a
high sensitivity and one for a patient with very low
sensitivity are presented in Fig. 1.
Means and standard deviations of the regression lines are
presented in Table 2.b There were no relations between
participants’ sensitivity and objective measures of disease
severity: all the correlations between the slopes and
baseline FEV1 levels were o0.13 and not significant (all
P’s40.5c). Similarly, the correlations between the slopesbFor 10 participants, slopeAffective could not be calculated because
they rated the same level of affective symptoms throughout the
histamine provocation. This was also the case for slopeSensory for 1
participant. Theoretically, these participants should have had a
‘flat’ slope (slope ¼ 0) assigned. Because assigning zero to 10 out of
25 subjects would have skewed the distribution of the slopeAffective,
we excluded participants with a flat slope from correlational
analyses. n’s are reported.and the provocative dose of histamine causing a 20% fall in
FEV1 (PC20) were not significant: r ¼ 0.24; 0.15 and
0.41 for slopeTotal, slopeSensory, and slopeAffective, respec-
tively.
In contrast, we observed a relation between participants’
sensitivity and (subjective) symptom reports: there was a
substantial correlation between the absolute perceptual
magnitude (PS20) and the slopeTotal: r ¼ 0.46, Po0.05.
Similarly, the correlation between participants’ sensitiv-
ity and subjective symptoms at baseline (ASC-Now) was
significant, r ¼ 0.46, Po0.05.Differentiation between sensory and affective
aspects of dyspnea
Overall, slopeSensory was significantly higher than slopeAffective,
t(47) ¼ 3.88, Po0.001. This difference was also significant
when only the patients with a slopeAffective40 were included,
t(37) ¼ 2.34, Po0.05. The correlation between PS20 and
slopeAffective was high (r ¼ 0.50, n ¼ 15, P ¼ 0.055), whereas
the correlation for slopeSensory was much lower (r ¼ 0.27,
n ¼ 24, n.s.). So, especially those patients who reported morecA comparison between the patients who used Inhaled Corticos-
teroids to control their disease and the remainder of the group
revealed that there were no significant differences in the mean
slopes between the groups, all F’so1.
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Table 2 Clinical characteristics of the study population
and mean slopes.
Patients (n ¼ 25)
PC20 (mg/ml)* 1.57 (1.51–2.75)
# Histamine inhalations 4.271.4
Baseline FEV1 (% pred) 96.6713.9
FEV1 change after NaCl (% pred) 1.772.5
Slopes of the regression line
between change in FEV1 and
ASC-Short Total (n ¼ 25) 0.32 (0.30)
ASC-Short Sensory (n ¼ 24) 0.58 (0.45)
ASC-Short Affective (n ¼ 15) 0.26 (0.36)
Note: Data are presented as Mean7SD, except for: *:
geometric mean (95% confidence interval). PC20: provocative
concentration of histamine causing a 20% fall in FEV1; % pred:
percentage of predicted value.
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Figure 1 Two examples of linear regression slopes. The left pannel shows the data of a patient with a high sensitivity for changes in
lung function (patient 20; slope ¼ 1.49); the right pannel shows the data of a patient with a very low sensitivity for changes in lung
function (patient 23; slope ¼ 0.07). The X-axis shows the percentage decline in lung function compared to post-saline values, the Y-
axis shows the increase in symptoms compared to post-saline values.
Sensory/affective aspects of bronchoconstriction 929affective complaints as their lung function decreased reported
more complaints at a 20% fall in lung function.
A similar pattern was observed for asthma complaints
during an exacerbation in daily life, although the correla-
tions were not significant (r ¼ 0.26, n ¼ 13 and 0.02, n ¼ 21
for slopeAffective and slopeSensory, respectively, n.s.).Psychological variables and symptom perception
Anxiety
The partial correlation (i.e., controlled for baseline FEV1)
between trait anxiety and PS20 was 0.23, n ¼ 25, n.s. The
partial correlation between trait anxiety and the slopeTotal
was 0.30, n ¼ 25, n.s. In contrast, there was a strong effect
of baseline (state) anxiety: patients who reported more
anxiety before the start of the histamine provocation (ASC-
Now), also reported more complaints in general (slopeTotal)
as their lung function decreased, r ¼ 0.55, n ¼ 24, Po0.01.
The correlation between baseline anxiety symptoms and
slopeAffective was slightly lower but still significant, r ¼ 0.55,n ¼ 15, Po0.05, whereas the correlation with slopeSensory
was only 0.31, n ¼ 23, n.s. This pattern of results was even
more obvious when we controlled for baseline FEV1:
r ¼ 0.55, n ¼ 24, Po0.01; r ¼ 0.57, n ¼ 15, P ¼ 0.05; and
r ¼ 0.29, n ¼ 23, n.s. for slopeTotal, slopeAffective, and
slopeSensory, respectively.
Nevertheless, the partial correlation between baseline
anxiety (ASC-Now) and PS20 was small and not significant,
r ¼ 0.19, n ¼ 24, n.s.
Catastrophizing about asthma
The correlations between CAS scores and the slopes are
presented in Table 3. In contrast to anxiety ratings,
catastrophic thoughts and feelings during an asthma
exacerbation were more strongly related to the reporting
of sensory complaints than to the reporting of affective
complaints during histamine induced bronchoconstriction.
Moreover, we observed strong partial correlations (con-
trolled for baseline FEV1) between the ‘general’ scale
and symptom reports at baseline (ASC-Now; all r’s40.30)
with significant correlations for anxiety and dyspnea
symptoms.
Relative weight of psychological variables
Forward stepwise multiple regression analysis with the
slopes as dependent variables and anxiety scores at base-
line, trait anxiety, catastrophizing scores, and baseline FEV1
values as predictors retained both anxiety scores at baseline
and CAS ‘exacerbation’ scores in the model for slopeTotal,
b’s ¼ 0.48 and 0.29, respectively, adj. R2 ¼ 0.34, F(2,
20) ¼ 6.62, Po0.01. For slopeAffective, only anxiety scores
at baseline were retained, b ¼ 0.55, explaining 24% of the
variance, F(1, 12) ¼ 5.22, Po0.05, whereas for slopeSensory,
only CAS ‘exacerbation’ scores were retained, b ¼ 0.54,
explaining 23% of the variance F(1, 20) ¼ 7.49, Po0.05.
Comparison between patients with a ‘flat’
slopeAffective and a slopeAffective40
There were no significant differences between the 10
patients with a flat slopeAffective and the other patients in
terms of baseline FEV1, change in FEV1 after NaCl inhalation,
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Table 3 Correlations between CAS scores on the one hand and slopes and symptoms at baseline on the other hand.
Catastrophizing exacerbation scale Catastrophizing general scale
SlopeTotal (n ¼ 24) 0.41 0.40
SlopeSensory (n ¼ 23) 0.51 0.33
SlopeAffective (n ¼ 14) 0.14 0.45
ASC-Now 0.23 0.55
Obstruction 0.02 0.39
Dyspnea 0.10 0.55
Anxiety 0.35 0.75
Irritability 0.26 0.34
Fatigue 0.17 0.31
Hyperventilation 0.25 0.31
Partial correlations (controlled for baseline FEV1 values), n ¼ 23.
Po0.05.
S. De Peuter et al.930or baseline symptom reports. Patients with a flat slopeAffective
showed a tendency to have more severe airway reactivity,
however: they reached a 20% fall in FEV1 at 1.5mg/ml
histamine (PC20) on average, compared to 2.6mg/ml for the
other group, F(1, 23) ¼ 3.80, P ¼ 0.06.
The group with a flat slopeAffective scored significantly
lower on trait anxiety (M ¼ 19.4, SD ¼ 5.5) compared to
patients with a higher slopeAffective (M ¼ 26.2, SD ¼ 5.5), F(1,
23) ¼ 9.18, Po0.01; they had significantly lower baseline
anxiety levels (ASC-Now) than the group with a higher
slopeAffective, M7SD ¼ 0.370.5 and 1.571.6, respectively
(Mann–Whitney U-test: 2 1 sided exact Po0.05); and they
had a tendency to report less anxiety during an exacerbation
in daily life, M7SD ¼ 1.770.6 and 2.471.0, respectively,
F(1, 20) ¼ 3.13, P ¼ 0.09. Finally, patients with a flat
slopeAffective also had lower slopeSensory (M ¼ 0.40,
SD ¼ 0.14) than patients with a higher slopeAffective
(M ¼ 0.70, SD ¼ 0.12), although this difference was not
significant, F(1, 22) ¼ 2.70, P ¼ 0.11.Discussion
We investigated symptom perception in patients with
asthma during a histamine provocation. The slope of the
regression line between the decrease in lung function and
the increase in subjective symptoms was used as a measure
of overall perceptual sensitivity and for sensory and
affective symptoms separately.
There was no relation at baseline between subjective
symptoms and lung function, probably due to temporal
adaptation to pre-existing obstruction32,33: at the end of the
histamine provocation there was a correlation between
changes in subjective symptoms and lung function. In
contrast to previous findings,3,4,34 we found no relation
between the participants’ perceptual sensitivity for dyspnea
and physiological measures of disease severity such as FEV1
and histamine dose level at 20% decrease of FEV1.
The distinction between sensory and affective aspects of
dyspnea proved to be clinically relevant. Slopes for sensory
symptoms were much higher than slopes for affective
symptoms. Whereas all patients reacted to the histamine
challenge with sensory symptoms, 10 out of 24 patientsshowed no affective response at all. Nevertheless, espe-
cially those patients whose affective symptoms increased as
their lung function decreased ended up reporting more
symptoms. Patients with higher trait anxiety reported a
stronger increase in symptoms with decreasing lung function
and, specifically for affective symptoms, patients with
higher baseline anxiety were significantly more sensitive
compared to patients with low baseline anxiety. In contrast,
the relation between state anxiety and sensory symptoms
was not significant.
A relation between depression/anxiety and symptom
reports in asthma has been reported before35 and emotional
status is a determinant of clinical dyspnea scores.36
However, Spinhoven and colleagues5 did not observe effects
of baseline anxiety. They suggested a curvilinear relation
between anxiety and symptom reporting and reported that
their study group had an average of 5.7 previous histamine
provocations, probably putting them at ease. We did not
record the number of previous histamine provocations our
participants had experienced, but most patients indicated
that the procedure was new to them and that they did not
know what to expect. This uncertainty may have induced
anxious expectancies and, consequently, baseline anxiety.
The specific relationship between anxiety and affective
sensitivity was supported by the results of the linear
regression analyses, whereas sensitivity for physical symp-
toms was best predicted by catastrophic thinking during an
asthma exacerbation. Spinhoven et al. did not observe this
relation between catastrophic thoughts and symptom
perception.5 However, they used a general measure of
catastrophic thinking, assessing catastrophic thoughts about
everyday situations, whereas the current study included a
disease-specific measure.
The current study has some limitations. First, patients’
asthma was not well controlled and for some patients we
were not able to determine asthma severity according to
GINA guidelines. This may restrict the generalizability of our
results to the broader asthma population. Furthermore, our
sample was selected from patients referred for histamine
challenge. As the majority of persons with asthma do not
undergo histamine or other challenge procedures, the same
critique applies. Second, the validity of bronchial provoca-
tion tests for examining perceptual sensitivity has been
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episodes of spontaneous bronchoconstriction.3,37 Patients
will probably be more focused on their respiratory sensa-
tions in the laboratory compared to daily life. In addition,
the laboratory setting with medical staff present may
reduce or increase anxiety and influence symptom percep-
tion. Nevertheless, our results support the validity of
histamine provocations: the relations between the patients’
perceptual sensitivity and the levels of symptoms at a 20%
fall in lung function were similar to the relations between
patients’ perceptual sensitivity and their symptom reports
during an asthma exacerbation in daily life.
These results have important clinical implications. A high
sensitivity seems favorable, because it allows the early
detection of deteriorating lung function and quick medica-
tional relief.3 However, a high sensitivity is often associated
with overperception of symptoms and it is unclear at which
level sensitivity becomes maladaptive. To investigate this,
two problems have to be solved: First, overperception
should be defined. A variety of methods is used to measure
the perception of dyspnea/bronchoconstriction, such as
Borg scales, visual analogue scales and symptom ratings,
either or not calculating slopes,1,3,4,34 complicating com-
parison across studies. Second, normative data are needed
to determine (mal)adaptive levels of perceptual sensitivity.
We have argued before that a moderate degree of
asthma-specific anxiety is adaptive because it is a good
incentive to take action when symptoms emerge and may be
associated with enhanced perception of bronchoconstric-
tion.38 In contrast, the absence of anxiety may lead to
indifference and neglect of symptoms; high illness-specific
anxiety may lead to overperception.39 Again, this ‘optimal
level of anxiety’ should be determined.
The relationship between sensitivity and perception
should be extended to include disease outcome variables
such as long-term development of the disease, medication
compliance and self-management of asthma. Bijl-Hofland
and colleagues3,4 reported that the 25% worst perceivers of
their patient sample reported very little symptoms in
combination with a more severe degree of asthma. In the
current study, 40% of the sample did not react emotionally
to the histamine inhalation. These patients were less
anxious and tended to have higher airway reactivity than
the patients who reacted emotionally. In addition, they
showed somewhat lower sensitivity for sensory symptoms,
suggesting a possible link between the absence of an
affective response and underperception. Bijl-Hofland and
colleagues suggest that these patients should receive more
supervision from physicians, with treatment plans that may
consist of training for peak flow monitoring. Our results
further suggest that the treatment plan of overperceivers
may best be aimed at reducing anxiety and, by extension,
coping with the emotional impact of the disease.Acknowledgements
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